XTLB - XTL Biopharmaceuticals Ltd.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
1.92
-0.07 (-3.34%)
At close: 3:38PM EST
Stock chart is not supported by your current browser
Previous Close1.99
Open1.90
Bid0.00 x 0
Ask0.00 x 0
Day's Range1.90 - 1.98
52 Week Range1.84 - 4.14
Volume5,483
Avg. Volume6,224
Market Cap9.028M
Beta0.20
PE Ratio (TTM)N/A
EPS (TTM)-0.50
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est30.00
Trade prices are not sourced from all markets
  • ACCESSWIRE2 months ago

    Wired News – Medigene Announced Collaboration with RXi Pharma to Further Improve its Therapeutic T Cells

    Stock Monitor: XTL Biopharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / December 13, 2017 / Active-Investors issued a free report on RXi Pharmaceuticals Corp. (NASDAQ: RXII ), which is readily accessible ...

  • PR Newswire3 months ago

    XTL Biopharmaceuticals Ltd. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Listing Requirements

    XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing treatments for autoimmune diseases, today announced that it has received notification from the NASDAQ Stock Market LLC ("NASDAQ") that the Company has regained compliance with the minimum $2.5 million stockholders' equity requirement for continued listing on The Nasdaq Capital Market. As previously disclosed, on October 17, 2017, the Company received a notice from NASDAQ stating that the Company was not in compliance with Nasdaq Listing Rule 5550(b)(1) (the "Stockholders' Equity Rule") because the Company did not have a minimum stockholders' equity, as of June 30, 2017, of $2.5 million and the Company did not alternatively meet the market capitalization or income from continuing operations tests.

  • PR Newswire3 months ago

    XTL Biopharmaceuticals Reports Third Quarter 2017 Financial Results

    RAANANA, Israel , Nov. 27, 2017 /PRNewswire/ -- XTL Biopharmaceuticals Ltd.  (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing ...

  • ACCESSWIRE5 months ago

    Corporate News Blog - Catabasis Pharma Shares Positive Results from Phase-2 MoveDMD Trials for Assessing Edasalonexent for Treatment of Duchenne Muscular Dystrophy

    Research Desk Line-up: XTL Biopharma Post Earnings Coverage LONDON, UK / ACCESSWIRE / October 6, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Catabasis ...

  • ACCESSWIRE5 months ago

    Earnings Review and Free Research Report: DelMar Missed Earnings Expectations

    Research Desk Line-up: XTL Biopharma Post Earnings Coverage LONDON, UK / ACCESSWIRE / October 5, 2017 / Pro-Trader Daily has just published a free post-earnings coverage on DelMar Pharmaceuticals, Inc. ...

  • PR Newswire5 months ago

    XTL Biopharmaceuticals Reports First Half 2017 Financial Results & Provides Clinical and Operational Update

    RAANANA, Israel , Sept. 26, 2017 /PRNewswire/ -- XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) (TASE: XTLB.TA)("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing ...

  • PR Newswire5 months ago

    XTL Biopharmaceuticals Unveils Additional Expanded hCDR1 Preclinical Data for the Treatment of Sjogren's Syndrome

    HERTZLIYA, Israel, Sept. 12, 2017 /PRNewswire/ -- XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing treatments for autoimmune diseases, today announced the Company has received additional preclinical data regarding the role of hCDR1 as a potential treatment for Sjögren's syndrome (SS) from Prof. Edna Mozes of The Weizmann Institute of Science and the developer of hCDR1. The Company has filed a third patent application with the U.S. Patent and Trademark Office for hCDR1 in the treatment of SS. The expansion of these in-vitro data includes peripheral blood mononuclear cells (PBMC) obtained from additional blood samples from patients with primary SS.

  • Accesswire7 months ago

    Featured Company News – Inotek Pharma Announces Top-line Results of Phase-2 FDC Trial of Trabodenoson and Offers Corporate Update

    Research Desk Line-up: XTL Biopharmaceuticals Post Earnings Coverage LONDON, UK / ACCESSWIRE / July 11, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines ...

  • PR Newswire8 months ago

    XTL Biopharmaceuticals Reports First Quarter 2017 Financial Results & Provides Clinical and Operational Update

    RAANANA, Israel , June 15, 2017 /PRNewswire/ -- XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing ...

  • PR Newswire10 months ago

    XTL Biopharmaceuticals Appoints Mr. Alex Rabinovich to its Board of Directors

    XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing treatments for autoimmune diseases, today announced that Mr. Alex Rabinovich has been appointed as a member of the Company's board of directors. Mr. Rabinovich is a leading investor in XTL and holds over 20% of its shares. Mr. Rabinovich will replace Mr. David Bassa, who has resigned from his position as a director of the Company, after serving as a director for seven years.

  • PR Newswire11 months ago

    XTL Biopharmaceuticals Unveils Expanded hCDR1 Preclinical Data for the Treatment of Sjögren’s Syndrome

    RAANANA, Israel, April 5, 2017 /PRNewswire/ -- Additional data shows a statistically significant effect in the gene expression of two additional genes that have a role in the pathogenesis of Sj ö gren ...

  • PR Newswire11 months ago

    XTL Biopharmaceuticals Reports 2016 Financial Results & Provides Clinical and Operational Update

    RAANANA, Israel, March 30, 2017 /PRNewswire/ --  XTL Biopharmaceuticals Ltd.  (NASDAQ: XTLB; TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing ...

  • PR Newswire11 months ago

    XTL Biopharmaceuticals Announces Closing of $2.8 Million Private Placement From Existing Investors

    XTL Biopharmaceuticals Ltd. (XTLB) (XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing treatments for autoimmune diseases, today announced that it has closed its private offering of securities for proceeds of $2.8 million. In connection with the offering, announced previously on March 7, 2017, the Company issued and sold 1,400,000 American Depository Shares (ADSs) at a purchase price of $2.00 per ADS. The Company has agreed to hold a shareholder meeting to increase its authorized ordinary shares to allow for the full exercise of the warrants (the "Authorized Capital Increase").

  • PR Newswirelast year

    XTL Biopharmaceuticals Announces $2.8 Million Private Placement From Existing Investors

    XTL Biopharmaceuticals Ltd. (XTLB) (XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing treatments for autoimmune diseases, today announced that it has entered into definitive agreements with existing investors to receive proceeds of $2.8 million in a private placement offering. In connection with the offering, the Company will issue 1,400,000 American Depository Shares (ADSs) at a purchase price of $2.00 per ADS, one cent below yesterday's closing price.  Additionally, for each ADS purchased by investors, the investors will receive an unregistered warrant to purchase one ADS.  The Company has agreed to hold a shareholder meeting to increase its authorized ordinary shares to allow for the full exercise of the warrants (the "Authorized Capital Increase").

  • PR Newswirelast year

    XTL Biopharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Listing Requirement

    As previously disclosed on November 14, 2017, XTL received a letter from Nasdaq notifying the Company that it was not in compliance with Nasdaq's Listing Rule 5450(a)(1) because the minimum bid price of the Company's American Depositary Shares ("ADSs") had closed below US $1.00 per share for 30 consecutive business days. On February 28, 2017, XTL received notification from Nasdaq that the closing price of the Company's America Depository Share has been at $1.00 per share or greater for the last 10 consecutive business days from February 10 through 24, 2017.